Animal and human studies suggest yerba mate increases GLP-1 levels and reduces appetite, likely via polyphenols and gut stimulation
Studies Linking GLP-1 Medications to NAION Several peer-reviewed studies have confirmed an increased risk of NAION in patients taking GLP-1 drugs: Harvard Medical School & Mass General Brigham Study (JAMA Ophthalmology, 2024) 9% of diabetic patients taking semaglutide developed NAION, compared to 1.8% on other diabetes drugs (a 4-fold increased risk)
That is a verywhat I would callsoft call, but theres tremendous safety, and the benefit of the GLP-1 therapy to patients must be considered in light of the lack of evidence of any concern with regards to thyroid malignancy
However, manufacturers have begun streamlining access: Novo Nordisk now offers Wegovy (semaglutide) through the NovoCare Pharmacy Program, and Eli Lilly facilitates access to Zepbound via LillyDirect, its direct-to-patient pharmacy platform
GLP-1 (glucagon-like peptide-1) is a hormone made in the small intestine right after a meal
Research on human growth hormone confirms the pattern: maximum serum concentration arrived at 4.26 hours from the abdomen versus 5.89 hours from the thigh